Scandion Oncology A/S (SCOL.ST)
SEK 0.01
(4.39%)
SEK 0.01
(4.39%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -45.53 Million DKK | 43.66% |
| 2022 | -80.82 Million DKK | -44.74% |
| 2021 | -56.09 Million DKK | -144.36% |
| 2020 | -22.85 Million DKK | -48.57% |
| 2019 | -15.59 Million DKK | -54.83% |
| 2018 | - DKK | -2166.79% |
| 2017 | - DKK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.66 Million DKK | 15.57% |
| 2024 Q2 | -8.96 Million DKK | 7.21% |
| 2023 Q4 | -11.44 Million DKK | -13.17% |
| 2023 Q2 | -10.73 Million DKK | 5.75% |
| 2023 FY | - DKK | 43.66% |
| 2023 Q1 | -11.39 Million DKK | 33.71% |
| 2023 Q3 | -10.11 Million DKK | 5.79% |
| 2022 Q2 | -24.42 Million DKK | -51.94% |
| 2022 Q4 | -17.18 Million DKK | 25.48% |
| 2022 FY | - DKK | -44.74% |
| 2022 Q1 | -16.07 Million DKK | -4.37% |
| 2022 Q3 | -23.06 Million DKK | 5.57% |
| 2021 Q1 | -9.79 Million DKK | -6.85% |
| 2021 FY | - DKK | -144.36% |
| 2021 Q4 | -15.4 Million DKK | -0.87% |
| 2021 Q3 | -15.27 Million DKK | 0.07% |
| 2021 Q2 | -15.28 Million DKK | -55.95% |
| 2020 Q2 | -4.74 Million DKK | -17.64% |
| 2020 Q1 | -4.03 Million DKK | -247.04% |
| 2020 Q4 | -9.17 Million DKK | -87.05% |
| 2020 FY | - DKK | -48.57% |
| 2020 Q3 | -4.9 Million DKK | -3.32% |
| 2019 Q4 | -1.16 Million DKK | 83.47% |
| 2019 FY | - DKK | -54.83% |
| 2019 Q3 | -7.03 Million DKK | -44.92% |
| 2019 Q2 | -4.85 Million DKK | -106.87% |
| 2019 Q1 | -2.34 Million DKK | 57.95% |
| 2018 Q2 | -2.36 Million DKK | -240.42% |
| 2018 Q4 | -5.57 Million DKK | -330.38% |
| 2018 FY | - DKK | -2166.79% |
| 2018 Q1 | -695.13 Thousand DKK | -943.5% |
| 2018 Q3 | -1.29 Million DKK | 45.24% |
| 2017 Q3 | 238.04 Thousand DKK | 0.0% |
| 2017 FY | - DKK | 0.0% |
| 2017 Q4 | 82.41 Thousand DKK | -65.38% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| 2cureX AB (publ) | -35.13 Million SEK | -29.588% |
| Abliva AB (publ) | -93.6 Million SEK | 51.359% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 58.057% |
| AcouSort AB (publ) | -16.7 Million SEK | -172.598% |
| Active Biotech AB (publ) | -43.88 Million SEK | -3.748% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 108512.105% |
| Amniotics AB (publ) | -27.14 Million SEK | -67.749% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -3.81% |
| Aptahem AB (publ) | -10 Million SEK | -354.9% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -220.264% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 80.838% |
| BioInvent International AB (publ) | -312.7 Million SEK | 85.439% |
| BioArctic AB (publ) | 275.38 Million SEK | 116.534% |
| Biosergen AB | 228 Thousand SEK | 20070.175% |
| Biovica International AB (publ) | -119.5 Million SEK | 61.9% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 16.922% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 87.621% |
| Camurus AB (publ) | 562.54 Million SEK | 108.094% |
| Cantargia AB (publ) | -284.31 Million SEK | 83.985% |
| Corline Biomedical AB | -1.69 Million SEK | -2592.608% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -132.555% |
| CombiGene AB (publ) | -35.33 Million SEK | -28.854% |
| Cyxone AB (publ) | -20.41 Million SEK | -123.043% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -297.001% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 67.674% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 85.731% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -166.51% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 55.558% |
| Fluicell AB (publ) | -25.91 Million SEK | -75.704% |
| Genovis AB (publ.) | 64.57 Million SEK | 170.514% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 60.375% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 93.628% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 494.251% |
| Mendus AB (publ) | -97.84 Million SEK | 53.466% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 73.73% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -22.98% |
| I-Tech AB | 30.34 Million SEK | 250.048% |
| Intervacc AB (publ) | -68.98 Million SEK | 33.992% |
| Kancera AB (publ) | -61.88 Million SEK | 26.43% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -70.003% |
| LIDDS AB (publ) | -39.67 Million SEK | -14.777% |
| Lipum AB (publ) | -37.11 Million SEK | -22.665% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -276.173% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 244.988% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 2276700.0% |
| Nanologica AB (publ) | -62.11 Million SEK | 26.702% |
| NextCell Pharma AB | -40.98 Million SEK | -11.094% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 80.342% |
| OncoZenge AB (publ) | 7.26 Million SEK | 726.645% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -416.676% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -239.007% |
| Saniona AB (publ) | -69.69 Million SEK | 34.67% |
| Simris Alg AB (publ) | -22.36 Million SEK | -103.604% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -7.834% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -2089.038% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 14815.607% |
| SynAct Pharma AB | -222.7 Million SEK | 79.555% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 85.658% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 83.856% |
| Xintela AB (publ) | -53.47 Million SEK | 14.847% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 73.187% |
| Ziccum AB (publ) | -20.34 Million SEK | -123.832% |